Privium Fund Management’s UroGen Pharma URGN Stock Holding History

Privium Fund Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.28M	Buy	238,122 +23,500	+11%	+$471K	0.89%	25
2025 Q4	$5.03M	Buy	214,622 +18,000	+9%	+$390K	0.93%	22
2025 Q3	$3.92M	Buy	196,622 +89,000	+83%	+$1.6M	0.71%	23
2025 Q2	$1.4M	Hold	107,622	–	–	0.3%	25
2025 Q1	$1.19M	Buy	107,622 +79,931	+289%	+$852K	0.31%	31
2024 Q4	$295K	Buy	+27,691	New	+$332K	0.07%	53

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Privium Fund Management's URGN Position: Q1 2026 in Review

Privium Fund Management increased its UroGen Pharma (URGN) stake by 11% in Q1 2026, buying an estimated $471K and bringing the position to 238,122 shares worth $4.28M. The position accounts for 0.89% of the portfolio, ranked #25.

Privium Fund Management first reported a position in URGN in Q4 2024 and has held it in 6 quarters since. The position peaked at $5.03M in Q4 2025. 172 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

Privium Fund Management held 238,122 shares of UroGen Pharma worth $4.28M as of Q1 2026.
Privium Fund Management bought 23,500 UroGen Pharma shares in Q1 2026, an estimated $471K.
UroGen Pharma made up 0.89% of Privium Fund Management's portfolio in Q1 2026, its #25 holding.
Privium Fund Management first reported a position in UroGen Pharma in Q4 2024 and has held it in 6 quarters since.
Privium Fund Management's UroGen Pharma position peaked at $5.03M in Q4 2025.
172 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Privium Fund Management's 13F filing for Q1 2026, filed 5 May 2026.